This company listing is no longer active
N4CN Stock Overview
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Paratek Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.02 |
| 52 Week High | US$3.65 |
| 52 Week Low | US$1.19 |
| Beta | 1.7 |
| 1 Month Change | 2.90% |
| 3 Month Change | n/a |
| 1 Year Change | -13.95% |
| 3 Year Change | -57.52% |
| 5 Year Change | -75.32% |
| Change since IPO | -86.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| N4CN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.4% | -3.9% | -2.8% |
| 1Y | -13.9% | -19.2% | 10.0% |
Return vs Industry: N4CN underperformed the German Pharmaceuticals industry which returned -3.5% over the past year.
Return vs Market: N4CN underperformed the German Market which returned 14.4% over the past year.
Price Volatility
| N4CN volatility | |
|---|---|
| N4CN Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: N4CN has not had significant price volatility in the past 3 months.
Volatility Over Time: N4CN's weekly volatility has decreased from 15% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 269 | Evan Loh | www.paratekpharma.com |
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd.
Paratek Pharmaceuticals, Inc. Fundamentals Summary
| N4CN fundamental statistics | |
|---|---|
| Market cap | €119.98m |
| Earnings (TTM) | -€58.88m |
| Revenue (TTM) | €166.13m |
0.7x
P/S Ratio-2.0x
P/E RatioIs N4CN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N4CN income statement (TTM) | |
|---|---|
| Revenue | US$177.00m |
| Cost of Revenue | US$64.13m |
| Gross Profit | US$112.87m |
| Other Expenses | US$175.60m |
| Earnings | -US$62.73m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09 |
| Gross Margin | 63.77% |
| Net Profit Margin | -35.44% |
| Debt/Equity Ratio | -128.3% |
How did N4CN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/22 04:01 |
| End of Day Share Price | 2023/09/20 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Paratek Pharmaceuticals, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| Timothy Chiang | BTIG |